Aetion scientists, working in partnership with our colleagues at Moderna, recently published the study "Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States" in the journal Vaccine. This important work helps us continue to understand the relative effectiveness of different vaccine options and remains crucial in protecting vulnerable populations. https://hubs.li/Q02HQhvr0
About us
Aetion is a health care analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care’s most critical decisions — what works best, for whom, and when — to guide product development, commercialization, and payment innovation. Aetion is based in New York City and backed by investors including New Enterprise Associates (NEA), Warburg Pincus, Flare Capital Partners, Greenspring Associates, Lakestar, B Capital, Foresite Capital, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, EDBI, Johnson & Johnson Innovation—JJDC, Inc., UCB, Amgen Ventures, and Horizon Health Services, Inc. Learn more at aetion.com and follow us at @aetioninc.
- Website
-
http://aetion.com
External link for Aetion
- Industry
- Software Development
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2012
Locations
-
Primary
5 Penn Plaza
7th Floor
New York, NY 10001, US
-
50 Congress St
Suite 1025
Boston, Massachusetts 02109, US
-
Carrer Córcega, 381-387
Planta 4 (4th Floor)
Barcelona, 08037 , ES
Employees at Aetion
Updates
-
In a recent episode of Executive Leaders Radio Podcast, Aetion CEO Carolyn M. joins a panel of driven and impactful leaders from the business community to share how her childhood experiences shaped her career today. Tune in here to check out the full interview: https://hubs.li/Q02HPcgh0
Podcast: Top leadership share stories of their childhood and how it guided them into leadership roles later in life
evidence-hub.aetion.com
-
ICYMI - Now available on the Aetion Evidence Hub, discover how Partial Longitudinal Synthesis (PLS) offers a breakthrough solution for creating high-utility, privacy-compliant synthetic health data. Learn more here: https://hubs.li/Q02G_PZX0 #HealthData #SyntheticData #Privacy
Efficient Synthesis of Complex Health Data
evidence-hub.aetion.com
-
Join Nicholaas Honig (Head of Regulatory and Sr. Counsel at Aetion) as he speaks at the Duke-Margolis Institute for Health Policy's 2024 State of RWE Policy webinar, Session 2 alongside Trevan Locke, PhD, Stella Chang, Dena Jaffe Hirschfield, and Katy Sadowski. Register using the link below to attend this engaging discussion on how to ensure source data access for health care decision-makers: https://hubs.ly/Q02GNM4v0
Welcome! You are invited to join a webinar: 2024 State of Real-World Evidence Policy. After registering, you will receive a confirmation email about joining the webinar.
duke.zoom.us
-
The FDA, as part of the Prescription Drug User Fee Act (PDUFA VII), has committed to reporting aggregate and anonymized information on submissions containing real-world evidence (RWE) to the Center for Biologics Evaluation and Research (CBER) and the Center for Drug Evaluation and Research (CDER). This ongoing reporting aims to enhance understanding and confidence in the integration of #RWE in regulatory decision-making processes. This report includes: 📝 Protocols: FDA reviewed 10 RWE protocols in 2023, with 1 focused on effectiveness and 9 on safety. All 10 aimed to satisfy post-marketing requirements or commitments. 💡 Applications: FDA reviewed 4 applications in 2023 containing de novo RWE for effectiveness or safety purposes. ✅ Approvals Based on RWE: The FDA approved two drugs, Actemra (Genentech) and Vimpat (UCB), based at least in part on RWE. Read more here: https://hubs.li/Q02G5mTh0
-
-
ICYMI - Aetion has achieved its first FDA device clearance and label change using real-world data (RWD), collaborating with Intuitive, FDA, and NEST. The revised labeling for Intuitive’s da Vinci X and Xi systems is based on RWD, showing similar long-term survival rates for robotic-assisted and non-robotic radical prostatectomy, showcasing the power of RWD in advancing cancer treatment and regulatory science. Learn more here: https://hubs.li/Q02FggSc0 #Innovation #Healthcare #RoboticSurgery #CancerTreatment #FDA #RWD
Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy | Intuitive Surgical
isrg.intuitive.com
-
Empowering Healthcare: Global Efforts for Transparent AI in Medical Devices The FDA, Health Canada | Santé Canada, and the U.K. Medicines and Healthcare products Regulatory Agency are collaborating to ensure transparency in #AI-powered medical devices. Building on their 2021 set of best practices, the latest guidelines emphasize transparency for all stakeholders, including health professionals, patients, administrators, payors, and governing bodies. It is our stance that the adoption of AI technologies in health care could lead to great improvements in efficiency, patient care and medical research, accelerating the discoveries that lead to new cures. And as this update outlines specifically for machine learning-enabled medical devices, transparency is a good practice for all applications of AI. Learn more: https://hubs.li/Q02DYWCn0
-
-
Swift insights are crucial for healthcare’s most critical decisions. With Aetion Discover, we bring together our top-tier analytics capabilities with a user-centric interface to serve up insights that are quick, clear, and reliable. Schedule a demo here: https://hubs.li/Q02DYCGp0
-
-
Unlock the potential of sensitive data with Aetion® Generate. Click the link to schedule a demo with us to learn how generative AI is helping users get more from their real-world and clinical data: https://hubs.li/Q02DtvH20
-
-
Now live on the Aetion Evidence Hub, discover how a recent study with Aetion, EMA, and the TREAT-NMD network using #RWD is shaping the future of Spinal Muscular Atrophy research. Find out how registry data is advancing treatment options for rare diseases like SMA. #RareDisease #RealWorldData #SMAResearch. Learn more here: https://hubs.li/Q02DpQqj0
Advancing SMA Treatment: How Real-World Evidence Supports Regulatory Decisions